Skip to main content

Kadcyla FDA Approval History

FDA Approved: Yes (First approved February 22, 2013)
Brand name: Kadcyla
Generic name: ado-trastuzumab emtansine
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Breast Cancer

Kadcyla (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate indicated for the treatment of patients with HER2-positive, metastatic breast cancer.

Development timeline for Kadcyla

May  3, 2019Approval FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer
Feb 22, 2013Approval FDA Approves Kadcyla for Late-Stage Breast Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.